A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
PMV Pharmaceuticals, Inc
Mayo Clinic
Genmab
Seagen Inc.
Tizona Therapeutics, Inc
Eli Lilly and Company
Seagen Inc.
Sairopa B.V.
Eli Lilly and Company
Merck Sharp & Dohme LLC
Tempest Therapeutics
NuCana plc
Medicenna Therapeutics, Inc.
Inspirna, Inc.
GV20 Therapeutics
Carisma Therapeutics Inc
NextCure, Inc.
Corvus Pharmaceuticals, Inc.
Xencor, Inc.
Silverback Therapeutics
Incyte Corporation
Incyte Corporation
Incyte Corporation
Eisai Inc.